Q2 2024 Lineage Cell Therapeutics Inc Earnings Call Transcript
Key Points
- Lineage Cell Therapeutics Inc (LCTX) has successfully expanded its alliance with Roche and Genentech, reflecting positive developments in their OpRegen program.
- The company has opened its first ex-US clinical site for the OpRegen Phase 2 trial in Israel, enhancing the program's global reach.
- Lineage Cell Therapeutics Inc (LCTX) has a strong cash position with $38.5 million in cash, cash equivalents, and marketable securities, expected to support operations into Q4 2025.
- The company is making strategic investments in its pipeline, including promising preclinical programs like ANP1 for hearing loss and a new undisclosed neurology program.
- Lineage Cell Therapeutics Inc (LCTX) maintains a disciplined approach to fiscal management, allowing it to navigate the challenging biotech market environment effectively.
- The biotech sector remains in a prolonged bear market, affecting investor sentiment and capital availability for Lineage Cell Therapeutics Inc (LCTX).
- The company experienced a decrease in total revenues to $1.4 million, down from $3.2 million in the same period in 2023, primarily due to lower collaboration and licensing revenues.
- Lineage Cell Therapeutics Inc (LCTX) is facing delays in FDA review for its IND amendment related to the OPC1 program, impacting the timeline for initiating the DOSED study.
- The company reported a net loss of $5.8 million for the quarter, an increase from the $5.2 million loss in the same period in 2023.
- There is uncertainty regarding the timing and availability of clinical data from the OpRegen trial, as Lineage does not control the release of this information.
Welcome to the Lineage Cell Therapeutics second quarter 2024 conference call. At this time, all participants are in a listen only mode. An audio webcast of this call is available on the Investors section of Lineage website at www.lineagecell.com.
This call is subject to copyright. It is the property of Lineage and recordings, reproduction or transmission of this call without the express written consent of Lineage, are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call Ms. Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead.
Thank you. Good afternoon and thank you for joining us. a press release reporting our second quarter 2024 financial results was issued earlier today August 8, 2024, and can be found on the Investors section of our website.
Please note that today's remarks and responses to your questions
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
